{
    "organizations": [],
    "uuid": "e125d160bb8d579900d9648158b7c5b16d277673",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-intends-to-modi/brief-puma-biotechnology-intends-to-modify-characteristics-summary-in-neratinib-marketing-authorization-application-idUSFWN1P60Z1",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY\n* PUMA BIOTECHNOLOGY SAYS IT INTENDS TO MODIFY SUMMARY OF PRODUCT CHARACTERISTICS IN ITS MARKETING AUTHORIZATION APPLICATION FOR NERATINIB\n* PUMA BIOTECHNOLOGY SAYS TO MODIFY SUMMARY FOR NERATINIB TO FURTHER REFINE INTENDED POPULATION TO PATIENTS AT A HIGH RISK OF DISEASE RECURRENCE Source text: ( bit.ly/2D21ru9 ) Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-12T05:20:00.000+02:00",
    "crawled": "2018-01-12T18:43:15.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "inc",
        "say",
        "met",
        "committee",
        "medicinal",
        "product",
        "human",
        "use",
        "scientific",
        "advisory",
        "group",
        "oncology",
        "puma",
        "biotechnology",
        "say",
        "intends",
        "modify",
        "summary",
        "product",
        "characteristic",
        "marketing",
        "authorization",
        "application",
        "neratinib",
        "puma",
        "biotechnology",
        "say",
        "modify",
        "summary",
        "neratinib",
        "refine",
        "intended",
        "population",
        "patient",
        "high",
        "risk",
        "disease",
        "recurrence",
        "source",
        "text",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}